194 related articles for article (PubMed ID: 21615078)
1. Structure-based design of novel boronic acid-based inhibitors of autotaxin.
Albers HM; Hendrickx LJ; van Tol RJ; Hausmann J; Perrakis A; Ovaa H
J Med Chem; 2011 Jul; 54(13):4619-26. PubMed ID: 21615078
[TBL] [Abstract][Full Text] [Related]
2. Discovery and optimization of boronic acid based inhibitors of autotaxin.
Albers HM; van Meeteren LA; Egan DA; van Tilburg EW; Moolenaar WH; Ovaa H
J Med Chem; 2010 Jul; 53(13):4958-67. PubMed ID: 20536182
[TBL] [Abstract][Full Text] [Related]
3. Boronic acid-based inhibitor of autotaxin reveals rapid turnover of LPA in the circulation.
Albers HM; Dong A; van Meeteren LA; Egan DA; Sunkara M; van Tilburg EW; Schuurman K; van Tellingen O; Morris AJ; Smyth SS; Moolenaar WH; Ovaa H
Proc Natl Acad Sci U S A; 2010 Apr; 107(16):7257-62. PubMed ID: 20360563
[TBL] [Abstract][Full Text] [Related]
4. Structure-Activity Relationships of Small Molecule Autotaxin Inhibitors with a Discrete Binding Mode.
Miller LM; Keune WJ; Castagna D; Young LC; Duffy EL; Potjewyd F; Salgado-Polo F; Engel García P; Semaan D; Pritchard JM; Perrakis A; Macdonald SJ; Jamieson C; Watson AJ
J Med Chem; 2017 Jan; 60(2):722-748. PubMed ID: 27982588
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and biological evaluation of phosphonate derivatives as autotaxin (ATX) inhibitors.
Cui P; Tomsig JL; McCalmont WF; Lee S; Becker CJ; Lynch KR; Macdonald TL
Bioorg Med Chem Lett; 2007 Mar; 17(6):1634-40. PubMed ID: 17257836
[TBL] [Abstract][Full Text] [Related]
6. Benzoxaboroles-Novel Autotaxin Inhibitors.
Kraljić K; Jelić D; Žiher D; Cvrtila A; Dragojević S; Sinković V; Mesić M
Molecules; 2019 Sep; 24(19):. PubMed ID: 31547058
[TBL] [Abstract][Full Text] [Related]
7. Structural basis of substrate discrimination and integrin binding by autotaxin.
Hausmann J; Kamtekar S; Christodoulou E; Day JE; Wu T; Fulkerson Z; Albers HM; van Meeteren LA; Houben AJ; van Zeijl L; Jansen S; Andries M; Hall T; Pegg LE; Benson TE; Kasiem M; Harlos K; Kooi CW; Smyth SS; Ovaa H; Bollen M; Morris AJ; Moolenaar WH; Perrakis A
Nat Struct Mol Biol; 2011 Feb; 18(2):198-204. PubMed ID: 21240271
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and structure-activity relationships of tyrosine-based inhibitors of autotaxin (ATX).
East JE; Kennedy AJ; Tomsig JL; De Leon AR; Lynch KR; Macdonald TL
Bioorg Med Chem Lett; 2010 Dec; 20(23):7132-6. PubMed ID: 20951039
[TBL] [Abstract][Full Text] [Related]
9. Structural Basis for Inhibition of Human Autotaxin by Four Potent Compounds with Distinct Modes of Binding.
Stein AJ; Bain G; Prodanovich P; Santini AM; Darlington J; Stelzer NM; Sidhu RS; Schaub J; Goulet L; Lonergan D; Calderon I; Evans JF; Hutchinson JH
Mol Pharmacol; 2015 Dec; 88(6):982-92. PubMed ID: 26371182
[TBL] [Abstract][Full Text] [Related]
10. Pharmacophore development and application toward the identification of novel, small-molecule autotaxin inhibitors.
North EJ; Howard AL; Wanjala IW; Pham TC; Baker DL; Parrill AL
J Med Chem; 2010 Apr; 53(8):3095-105. PubMed ID: 20349977
[TBL] [Abstract][Full Text] [Related]
11. Development of Autotaxin Inhibitors: An Overview of the Patent and Primary Literature.
Castagna D; Budd DC; Macdonald SJ; Jamieson C; Watson AJ
J Med Chem; 2016 Jun; 59(12):5604-21. PubMed ID: 26745766
[TBL] [Abstract][Full Text] [Related]
12. Synthesis of novel 2-pyrrolidinone and pyrrolidine derivatives and study of their inhibitory activity against autotaxin enzyme.
Gerokonstantis DT; Nikolaou A; Magkrioti C; Afantitis A; Aidinis V; Kokotos G; Moutevelis-Minakakis P
Bioorg Med Chem; 2020 Jan; 28(2):115216. PubMed ID: 31864778
[TBL] [Abstract][Full Text] [Related]
13. Autotaxin structure-activity relationships revealed through lysophosphatidylcholine analogs.
North EJ; Osborne DA; Bridson PK; Baker DL; Parrill AL
Bioorg Med Chem; 2009 May; 17(9):3433-42. PubMed ID: 19345587
[TBL] [Abstract][Full Text] [Related]
14. Autotaxin inhibitors: a patent review (2012-2016).
Nikolaou A; Kokotou MG; Limnios D; Psarra A; Kokotos G
Expert Opin Ther Pat; 2017 Jul; 27(7):815-829. PubMed ID: 28447479
[TBL] [Abstract][Full Text] [Related]
15. Boronic Acid Group: A Cumbersome False Negative Case in the Process of Drug Design.
Katsamakas S; Papadopoulos AG; Hadjipavlou-Litina D
Molecules; 2016 Sep; 21(9):. PubMed ID: 27617984
[TBL] [Abstract][Full Text] [Related]
16. Benzyl and naphthalene methylphosphonic acid inhibitors of autotaxin with anti-invasive and anti-metastatic activity.
Gupte R; Patil R; Liu J; Wang Y; Lee SC; Fujiwara Y; Fells J; Bolen AL; Emmons-Thompson K; Yates CR; Siddam A; Panupinthu N; Pham TC; Baker DL; Parrill AL; Mills GB; Tigyi G; Miller DD
ChemMedChem; 2011 May; 6(5):922-35. PubMed ID: 21465666
[TBL] [Abstract][Full Text] [Related]
17. alpha- and beta-substituted phosphonate analogs of LPA as autotaxin inhibitors.
Cui P; McCalmont WF; Tomsig JL; Lynch KR; Macdonald TL
Bioorg Med Chem; 2008 Mar; 16(5):2212-25. PubMed ID: 18082408
[TBL] [Abstract][Full Text] [Related]
18. Hydroxamic Acids Constitute a Novel Class of Autotaxin Inhibitors that Exhibit in Vivo Efficacy in a Pulmonary Fibrosis Model.
Nikolaou A; Ninou I; Kokotou MG; Kaffe E; Afantitis A; Aidinis V; Kokotos G
J Med Chem; 2018 Apr; 61(8):3697-3711. PubMed ID: 29620892
[TBL] [Abstract][Full Text] [Related]
19. Lysophosphatidic acid produced by autotaxin acts as an allosteric modulator of its catalytic efficiency.
Salgado-Polo F; Fish A; Matsoukas MT; Heidebrecht T; Keune WJ; Perrakis A
J Biol Chem; 2018 Sep; 293(37):14312-14327. PubMed ID: 30026231
[TBL] [Abstract][Full Text] [Related]
20. Autotaxin is overexpressed in glioblastoma multiforme and contributes to cell motility of glioblastoma by converting lysophosphatidylcholine to lysophosphatidic acid.
Kishi Y; Okudaira S; Tanaka M; Hama K; Shida D; Kitayama J; Yamori T; Aoki J; Fujimaki T; Arai H
J Biol Chem; 2006 Jun; 281(25):17492-17500. PubMed ID: 16627485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
